WO2014065402A1 - Anticorps monoclonal anti-cd-40 humain, et utilisation correspondante - Google Patents

Anticorps monoclonal anti-cd-40 humain, et utilisation correspondante Download PDF

Info

Publication number
WO2014065402A1
WO2014065402A1 PCT/JP2013/078971 JP2013078971W WO2014065402A1 WO 2014065402 A1 WO2014065402 A1 WO 2014065402A1 JP 2013078971 W JP2013078971 W JP 2013078971W WO 2014065402 A1 WO2014065402 A1 WO 2014065402A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
human
antigen
antibody
amino acid
Prior art date
Application number
PCT/JP2013/078971
Other languages
English (en)
Japanese (ja)
Inventor
直樹 細見
石井　敬介
克志 甲田
富美子 野村
恵子 勝見
Original Assignee
株式会社ペルセウスプロテオミクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社ペルセウスプロテオミクス filed Critical 株式会社ペルセウスプロテオミクス
Priority to JP2014543361A priority Critical patent/JPWO2014065402A1/ja
Publication of WO2014065402A1 publication Critical patent/WO2014065402A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Definitions

  • the present invention relates to an anti-human CD40 monoclonal antibody useful as an antitumor agent and a pharmaceutical composition containing the same.
  • CD40 has been identified as an antigen that is expressed on the surface of human B cells (Non-patent Document 1). From the homology of amino acid sequences, the low-affinity NGF receptor, TNF receptor, CD27, OX40, CD30, etc. belong to the TNF receptor family One of the members.
  • CD40 is a type I membrane glycoprotein that can be used in various cell types such as B lymphocytes, dendritic cells, monocyte epithelial cells, fibroblasts, and certain tumor cells such as neoplastic human B cells. Is also known to be expressed.
  • Non-patent Document 2 The physiological ligand for CD40 is CD40 Ligand (CD154, gp39). CD40L is expressed in activated T lymphocytes and binds to CD40 on the surface of B lymphocytes, which regulates the differentiation and proliferation of B lymphocytes, avoiding spontaneous apoptosis of germinal center B lymphocytes It is responsible for the mechanism (Non-patent Document 3).
  • Non-Patent Documents 4-7) CD40 stimulation with certain stimulating CD40 antibodies or soluble CD40L directly inhibits B cell lymphoma growth (8, 9).
  • Non-patent Document 10 HCD122, which is an anti-CD40 antibody that completely inhibits the binding of CD40L, not a stimulating antibody, is known to recognize the 82-86th epitope of CD40 (Patent Document 1).
  • An object of the present invention is to provide a monoclonal antibody having a stimulating activity stronger than that of a conventional anti-CD40 monoclonal antibody.
  • the present inventor made antibodies against human CD40 and obtained many anti-CD40 monoclonal antibodies. Then, it was found that antibodies that specifically bind to the amino acid residues of the CD40 epitope 21-37 or 38-61 exist in these antibody groups. Furthermore, the present inventors have found that an antibody that binds to the CD40 epitope has a strong growth inhibitory activity against a cancer cell line that expresses the CD40 antigen, thereby completing the present invention.
  • the present invention provides the following [1] to [16].
  • [1] An anti-human CD40 monoclonal antibody or an antigen-binding fragment thereof having antiproliferative activity in the absence of effector cells against human CD40 antigen-expressing cells a) specifically binds to an epitope comprising amino acid residues 21-37 of the human CD40 amino acid sequence (SEQ ID NO: 1) or b) to an epitope comprising amino acid residues 38-61 of the human CD40 amino acid sequence (SEQ ID NO: 1)
  • An anti-human CD40 monoclonal antibody or an antigen-binding fragment thereof is an anti-human CD40 monoclonal antibody or an antigen-binding fragment thereof.
  • [2] The amino acid sequence shown in any one of the following 1) to 16) in the light chain variable region and the heavy chain variable region, or in the amino acid sequence, one or more amino acids are substituted, deleted, added or inserted,
  • the anti-human CD40 monoclonal antibody or the antigen-binding fragment thereof according to [1] which has an amino acid sequence having an identity level of at least 90% or more.
  • [5] The anti-human CD40 monoclonal antibody or antigen-binding fragment thereof according to any one of [1] to [4], which is derived from a mouse.
  • [6] The anti-human CD40 monoclonal antibody or antigen-binding fragment thereof according to [1], which is a humanized antibody.
  • amino acid sequence in which the light chain variable region and the heavy chain variable region are respectively represented by any of the following, or one or more amino acids in the amino acid sequence are substituted, deleted, added or inserted, and the level of identity is The anti-human CD40 monoclonal antibody or antigen-binding fragment thereof according to [6] or [7], which has an amino acid sequence of at least 90% or more.
  • a pharmaceutical composition comprising the anti-human CD40 monoclonal antibody or antigen-binding fragment thereof according to any one of [1] to [10].
  • An antitumor agent for a tumor expressing a human CD40 antigen comprising the anti-human CD40 monoclonal antibody or the antigen-binding fragment thereof according to any one of [1] to [10] as an active ingredient.
  • a method for treating a tumor expressing human CD40 antigen comprising administering the anti-human CD40 monoclonal antibody or antigen-binding fragment thereof according to any one of [1] to [10] to a patient in need thereof .
  • the anti-human CD40 monoclonal antibody of the present invention is an antibody having 21-37- or 36-61-th amino acid residues of human CD40 as an epitope, and strongly suppresses growth against tumor cells expressing CD40 antigen. It has activity and is useful as an anticancer agent.
  • FIG. 10 is a graph showing the growth rate of Ramos cells and MOLP-8 cells in the concentration change of the mouse antibody and humanized antibody according to Example 10 of the present invention. It is a figure which shows the anti-tumor effect in the tumor-bearing mouse model of Ramos cell by the humanized antibody which concerns on Example 11 of this invention. It is a figure which shows the sensitivity of Ramos cell, Raji cell, and MOLP-8 cell with respect to DM1SH which concerns on Example 12 of this invention.
  • the first isoform also known as “long isoform” or “isoform 1” is a 277 amino acid precursor polypeptide (SEQ ID NO: 1 (isoform 1 in GenBank accession number NP_001241)). Expressed, which has a signal sequence represented by the first 20 residues.
  • the second isoform also known as “short isoform” or “isoform 2” is expressed as a 203 amino acid precursor polypeptide, also represented by the first 20 residues.
  • CD40 antigen or “CD40” encompasses both short and long isoforms of CD40.
  • the anti-CD40 antibodies of the invention bind to an epitope of human CD40 as set forth herein below, which human CD40 is one of either the short or long isoforms of the cell surface antigen. It exists in the same position. “CD40” means “human CD40” unless otherwise noted.
  • CD40 antigen is presented on the surface of various cell types. “Characterizing expression” and “expressing” mean that all or a portion of the CD40 antigen is exposed to the outside of the cell. The displayed or expressed CD40 antigen may be fully or partially glycosylated.
  • CD40 epitope means a molecule (eg, a peptide) or a fragment of the molecule capable of immunoreacting with an anti-CD40 antibody, eg, a CD40 antigenic determinant recognized by a monoclonal antibody. Is included. CD40 antigen epitopes may be included in proteins, protein fragments, peptides and the like. An epitope is most commonly a protein, a short oligopeptide, an oligopeptide mimetic (ie, an organic compound that mimics the antibody binding properties of the CD40 antigen), or a combination thereof.
  • an “antibody” as used herein is a heterotetrameric glycoprotein, typically about 150,000 daltons, consisting of two identical light (L) chains and two identical heavy (H) chains. Is defined as Each light chain is covalently linked to the heavy chain by one disulfide bond to form a heterodimer. A heterotetramer is formed by a disulfide covalent bond between two identical heavy chains of such a heterodimer. The light and heavy chains are linked together by a single disulfide bond, but the number of disulfide bonds between the two heavy chains varies depending on the immunoglobulin isotype. Each heavy and light chain also has regularly spaced intrachain disulfide bridges.
  • Each heavy chain has a variable domain (V H ) at the end of the amino acid followed by 3 or 4 constant domains (C H 1, C H 2, C H 3, and C H 4), and C H 1 And a hinge region exists between C H 2.
  • Each light chain has two domains: an amino-terminal variable domain (V L ) and a carboxy-terminal constant domain (C L ).
  • V L domains are associated non-covalently with a V H domain, whereas the C L domain usually are covalently linked with C H 1 domain via a disulfide bond. Certain amino acid residues are thought to form an interface between the light chain variable domain and the heavy chain variable domain (Chothia et al., J MoI Biol 1985; 186: 651-663).
  • variable refers to the fact that a particular portion of a variable domain has a wide range of sequence differences between antibodies and is used for the binding and specificity of each particular antibody to that particular antigen. However, the variability is not evenly distributed throughout the variable domain of the antibody. The variability is concentrated in three segments called complementarity determining regions (CDRs) in both the light chain variable domain and the heavy chain variable domain. The more highly conserved part of the variable domain is called the framework region (FR).
  • CDRs complementarity determining regions
  • CDR complementarity-determining region
  • the three CDRs of each of the heavy and light chains are separated by a framework region (FR) containing sequences that tend to be less variable.
  • FR and CDR are arranged in the order of FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4.
  • FR's rough ⁇ -sheet configuration brings the CDRs in each chain close to each other and close to each other. The resulting configuration contributes to the antigen binding site, but not all CDR residues are directly involved in antigen binding.
  • FR residues and Ig constant domains are not directly involved in antigen binding, but contribute to antigen binding and / or mediate antibody effector functions. Some FR residues are at least three by directly non-covalently binding to the epitope, interacting with one or more CDR residues, and affecting the boundary between the heavy and light chains The method can have a significant effect on antigen binding. Constant domains are not directly involved in antigen binding, but have a variety of effects, including antibody involvement in antibody-dependent cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP). Mediates Ig effector function.
  • ADCC antibody-dependent cytotoxicity
  • CDC complement-dependent cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • the “antigen-binding fragment” includes a part of an intact antibody, preferably the antigen-binding region or variable region of the intact antibody.
  • antigen binding fragments include Fab, Fab ′, F (ab ′) 2 and Fv fragments; bispecific antibodies; linear antibodies (Zapata et. Al., Protein Eng 1995; 8 (10): 1057 -1062); single chain antibody molecules; as well as multispecific antibodies formed from antigen-binding fragments.
  • Fab two identical antigen-binding fragments
  • Fc this name has the ability to crystallize easily. Is reflected).
  • Pepsin treatment yields an F (ab ′) 2 fragment that has two antigen binding sites and can still crosslink with antigen.
  • “Fv” is the smallest antigen-binding fragment that contains a complete antigen recognition and binding site. In the two-chain Fv species, this region consists of a dimer of one heavy chain variable domain and one light chain variable domain that are tightly and non-covalently linked. In a single chain Fv species, one heavy chain variable domain and one light chain variable domain associate in a “dimeric” structure whose light and heavy chains are similar to the structure in a two chain Fv species. As such, it can be covalently linked by a flexible peptide linker. In this configuration, the three CDRs of each variable domain interact to define an antigen binding site on the surface of the V H -V L dimer. Together, the six CDRs provide antigen binding specificity for the antibody. However, even a single variable domain (or half of an Fv containing only three CDRs specific for the antigen) has the ability to recognize and bind the antigen, but with a lower affinity than the complete binding site.
  • the “light chains” of antibodies (immunoglobulins) from any vertebrate species are divided into two distinctly different types (called kappa ( ⁇ ) and lambda ( ⁇ )) based on the amino acid sequences of their constant domains. It is classified.
  • immunoglobulins Dependent on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins are classified into different classes. There are five major classes of human immunoglobulins: IgA, IgD, IgE, IgG and IgM. It is further divided into subclasses (isotypes) (for example, IgG1, IgG2, IgG3, IgG4, IgA and IgA2).
  • the heavy chain constant domains that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively.
  • the subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known. Different isotypes have different effector functions. For example, the human IgG1 and IgG3 isotypes mediate antibody-dependent cytotoxicity (ADCC) activity.
  • ADCC antibody-dependent cytotoxicity
  • Cytotoxic agent refers to a substance that inhibits or suppresses the function of cells and / or causes destruction of cells.
  • the term is intended to include chemotherapeutic agents as well as toxins (enzymatically active toxins of bacterial, fungal, plant or animal origin) and fragments thereof.
  • cytotoxic agents can be coupled to antibodies, such as humanized CD40 antibodies, using known standard procedures and used, for example, to treat patients for whom therapy with antibodies is indicated.
  • a “radioisotope” is a radionuclide such as I 131 , 1 125 , Y 90 and Re 186 and is coupled to an antibody such as a humanized CD40 antibody using known standard procedures, eg It can be used to treat patients for whom therapy is indicated.
  • Tumor expressing CD40 includes acute lymphocytic leukemia, chronic leukemia, lymphoma (eg, Hodgkin's disease or non-Hodgkin's disease), multiple myeloma, carcinoma (eg, colon cancer, pancreatic cancer, breast cancer, ovarian cancer) , Prostate cancer, squamous cell carcinoma, kidney cancer, lung cancer, or esophageal cancer).
  • lymphoma eg, Hodgkin's disease or non-Hodgkin's disease
  • carcinoma eg, colon cancer, pancreatic cancer, breast cancer, ovarian cancer
  • Prostate cancer squamous cell carcinoma
  • kidney cancer e.g., lung cancer, or esophageal cancer
  • Effective cell refers to a cell having strong attack power and processing ability in cellular immunity, and examples thereof include killer T cells, helper T cells, suppressor T cells, natural killer cells, and macrophages.
  • the antibody of the present invention or an antigen-binding fragment thereof is an anti-human CD40 monoclonal antibody or an antigen-binding fragment thereof having antiproliferative activity in the absence of effector cells against human CD40 antigen-expressing cells. And a) specifically binds to an epitope comprising amino acid residues 21-37 of the human CD40 amino acid sequence (SEQ ID NO: 1) or b) to an epitope comprising amino acid residues 38-61 of the human CD40 amino acid sequence (SEQ ID NO: 1) Anti-human CD40 monoclonal antibody or antigen-binding fragment thereof.
  • the anti-human CD40 monoclonal antibody of the present invention or an antigen-binding fragment thereof has growth inhibitory activity against human CD40 antigen-expressing cells in the absence of effector cells. More specifically, a. Reacts with cells stably expressing human CD40, b. Reacts against a human CD40 expressing cancer cell line, and c. Has the effect of suppressing proliferation of human CD40-expressing cancer cells.
  • the antibody of the present invention reacts with human CD40 stably expressing cells and human CD40 expressing cancer cells in FACS analysis at an antibody concentration of 1.0 ⁇ g / mL or less.
  • the antibody of the present invention can be obtained by culturing for 3 days in the presence of antibody 3.0 ⁇ g / mL against 1 ⁇ 10 5 cells / mL of Ramos cells (ATCC No. CRL-1596) which are human CD40-expressing cancer cells.
  • the growth rate of Ramos cells is 70% or less.
  • the antibody of the present invention has a CD40 amino acid residue after the 21st position in FACS analysis at an antibody concentration of 1.0 ⁇ g / mL on cells expressing 6 types of partial length CD40 shortened from the N-terminus of human CD40.
  • the antibody groups that have the characteristic of reacting to cells expressing partial length CD40 the antibody group that has the characteristic of not reacting to cells expressing partial length CD40 after the 40th amino acid residue of CD40, or the 62nd and subsequent parts It is a group of antibodies having characteristics that do not react with cells expressing long CD40.
  • the light chain variable region and the heavy chain variable region are amino acid sequences shown in any one of the following 1) to 16), or one or more amino acids are substituted or deleted in the amino acid sequence: Has an amino acid sequence that is added or inserted and has a level of identity of at least 90% or more.
  • the light chain variable region and the heavy chain variable region are each represented by any of the following amino acid sequences, or one or more amino acids in the amino acid sequence are substituted, deleted, added or inserted: And having an amino acid sequence having a level of identity of at least 90% or more.
  • the antibody that specifically binds to an epitope including amino acid residues 21-37 of the human CD40 amino acid sequence is preferably an antibody produced by a hybridoma shown in the following 1) to 8).
  • the antibody that specifically reacts with an epitope containing amino acid residues 38-61 of the human CD40 amino acid sequence is preferably an antibody produced by the hybridoma shown in the following 1) to 10). . 1) PPAT-071-03 2) PPAT-071-06 3) PPAT-071-07 4) PPAT-071-08 5) PPAT-071-11 6) PPAT-071-14 7) PPAT-071-15 8) PPAT-071-16 9) PPAT-071-17 10) PPAT-071-19
  • the antibody produced by the hybridoma is derived from a mouse, but can also be a humanized antibody.
  • the humanized antibody can be obtained, for example, by humanizing using the amino acid sequence containing the complementarity determining region CDR of the mouse-derived anti-human CD40 monoclonal antibody and the amino acid sequence of human immunoglobulin.
  • each of the light chain variable region and the heavy chain variable region is represented by any of the following amino acid sequences, or one or more amino acids in the amino acid sequence are substituted, deleted, added or inserted: Those having an amino acid sequence with an identity level of at least 90% or more are preferred.
  • SEQ ID NOs: 58 and 59 1) SEQ ID NOs: 58 and 59, 2) SEQ ID NOs: 60 and 61, 3) SEQ ID NOs: 62 and 59, 4) SEQ ID NOs: 63 and 64 5) SEQ ID NOs: 65 and 66, 6) SEQ ID NOs: 60 and 67, 7) SEQ ID NO: 68 and 61, or 8) SEQ ID NO: 69 and 70,
  • the number of amino acid substitutions, deletions, additions or insertions in the amino acid sequence representing the light chain variable region and the heavy chain variable region is preferably 1 to 10, more preferably 1 to 8, and more preferably 1 to 6. More preferably.
  • the level of amino acid sequence identity is preferably 91% or more, more preferably 93% or more, and still more preferably 95% or more.
  • an antibody that binds to human CD40 can be produced by a method known to those skilled in the art.
  • a monoclonal antibody-producing hybridoma can be basically produced using a known technique as follows. That is, using a CD40 protein or a CD40-expressing cell as a sensitizing antigen, a mammal is immunized according to a normal immunization method. The obtained immune cells can be fused with a known parent cell by an ordinary cell fusion method, and monoclonal antibody-producing cells can be selected by an ordinary screening method.
  • a monoclonal antibody can be produced as follows. First, a CD40 protein is obtained according to the amino acid sequence of CD40 shown in SEQ ID NO: 1, and this is used as a sensitizing antigen for obtaining an antibody. That is, a gene sequence encoding human CD40 is inserted into a known expression vector system to transform an appropriate host cell, and then stable expression of CD40 on the surface of the host cell is produced, or from the culture supernatant The target CD40 protein is purified by a known method.
  • this purified CD40 protein or CD40 stably expressing cells is used as a sensitizing antigen.
  • a partial peptide of CD40 can be used as a sensitizing antigen.
  • the partial peptide can also be obtained by chemical synthesis according to the amino acid sequence of human CD40.
  • the mammal to be immunized with the sensitizing antigen is not particularly limited, but is preferably selected in consideration of compatibility with the parent cell used for cell fusion. Animals such as mice, rats, hamsters, rabbits, monkeys and the like are used.
  • Immunization of animals with a sensitizing antigen is performed according to a known method.
  • a sensitizing antigen is injected into a mammal intraperitoneally or subcutaneously.
  • the sensitizing antigen is diluted to an appropriate amount with PBS (Phosphate-Buffered Saline), physiological saline or the like, mixed with an appropriate amount of an ordinary adjuvant, for example, Freund's complete adjuvant, if necessary, and emulsified.
  • an appropriate carrier can be used during immunization with the sensitizing antigen.
  • immune cells are collected from the mammal and subjected to cell fusion.
  • Preferable immune cells include spleen cells.
  • Mammalian myeloma cells are used as parent cells to be fused with the immune cells.
  • This myeloma cell is known in various known cell lines such as P3 (P3x63Ag8.653) (Kearney et al., J Immnol 1979; 123: 1548-1550), NS-1 (Kohler. G. and Milstein, C Eur J Immunol 1976; 6: 511-519), SP2 / 0 (Shulman, M. et al., Nature 1978; 276: 269-270) and the like are preferably used.
  • the cell fusion between the immune cells and myeloma cells is basically performed by a known method such as the method of Kohler and Milstein (Kohler. G. and Milstein, C., Methods Enzymol 1981; 73: 3-46). It can carry out according to etc.
  • the cell fusion is performed, for example, in a normal nutrient culture medium in the presence of a cell fusion promoter.
  • a cell fusion promoter for example, polyethylene glycol (PEG), Sendai virus (HVJ) or the like is used, and an auxiliary agent such as dimethyl sulfoxide can be added and used to increase the fusion efficiency as desired.
  • the usage ratio of immune cells and myeloma cells can be arbitrarily set.
  • the number of immune cells is preferably 1 to 10 times that of myeloma cells.
  • the culture medium used for the cell fusion for example, RPMI1640 culture medium suitable for growth of the myeloma cell line, MEM culture medium, and other normal culture liquids used for this type of cell culture can be used. Serum supplements such as fetal bovine serum (FBS) can also be used in combination.
  • FBS fetal bovine serum
  • a predetermined amount of the immune cells and myeloma cells are mixed well in the culture medium, and a PEG solution (for example, an average molecular weight of about 1000 to 6000) preliminarily heated to about 37 ° C. is usually 30-60% (
  • the target fusion cell (hybridoma) is formed by adding at a concentration of w / v) and mixing. Subsequently, cell fusion agents and the like that are undesirable for the growth of the hybridoma are removed by sequentially adding an appropriate culture medium and centrifuging to remove the supernatant.
  • the hybridoma thus obtained is selected by culturing in a normal selective culture solution, for example, a HAT culture solution (a culture solution containing hypoxanthine, aminopterin and thymidine). Culturing with the above HAT culture solution is continued for a sufficient time (usually several days to several weeks) for cells other than the target hybridoma (non-fused cells) to die. Subsequently, a normal limiting dilution method is performed, and screening and single cloning of a hybridoma that produces the target antibody are performed.
  • a normal selective culture solution for example, a HAT culture solution (a culture solution containing hypoxanthine, aminopterin and thymidine). Culturing with the above HAT culture solution is continued for a sufficient time (usually several days to several weeks) for cells other than the target hybridoma (non-fused cells) to die.
  • a normal limiting dilution method is performed, and screening and single cloning of
  • an antibody that reacts with CD40 can be selected by FACS analysis using CD40 stably expressing cells used as a sensitizing antigen or cancer cells characterizing the expression of CD40.
  • An antibody that reacts with CD40 can also be selected by ELISA using purified CD40 protein.
  • a promising method for selecting an antibody to be used for treatment is FACS analysis using cancer cells that characterize the expression of CD40.
  • the hybridoma producing the monoclonal antibody thus produced can be subcultured in a normal culture solution and can be stored for a long time in liquid nitrogen.
  • the hybridoma is cultured according to a usual method and obtained as a culture supernatant, or the hybridoma is administered to a mammal compatible therewith to proliferate, and as ascites The method of obtaining is adopted.
  • the former method is suitable for obtaining highly pure antibodies, while the latter method is suitable for mass production of antibodies.
  • Cross-reactivity test with antigens derived from animal species other than humans includes an antibody that cross-reacts with cynomolgus monkey CD40.
  • Analysis of cross-reactivity of antibodies with antigens of animal species other than humans can be performed by methods known to those skilled in the art, and can be performed by Western blotting or FACS using partial-length antigen-expressing cells. . Specifically, it can be determined by FACS analysis using cells expressing cynomolgus monkey CD40 or mouse CD40.
  • CD40 epitope mapping As a preferred embodiment of the present invention, the following two CD40 epitopes: 1) 21st-37th CD40 amino acid residue 2) An antibody that reacts with 38th-61st CD40 amino acid residue can be mentioned. Analysis of the epitope recognized by the antibody can be performed by methods known to those skilled in the art, and can be performed by Western blotting or FACS using a partial-length antigen-expressing cell. Specifically, it can be analyzed by FACS using cells expressing six types of partial length CD40 excluding the N-terminal amino acid residue described in the Examples.
  • an antibody that recognizes the above region as an epitope can be obtained by methods known to those skilled in the art.
  • a peptide containing the amino acid sequence of the target region is prepared based on the amino acid sequence of human CD40, and the peptide Can be obtained by preparing an antibody using as an immunogen, or by determining the epitope recognized by the obtained antibody and selecting an antibody that recognizes the target epitope after preparing the antibody by a conventional method. Is possible.
  • Proliferation assay As a preferred embodiment of the present invention, an antibody that stimulates cells expressing CD40, that is, an antibody that suppresses proliferation of tumor cells expressing CD40 can be mentioned.
  • the measurement of the proliferation assay can be performed by a method known to those skilled in the art, and can be performed by a method of incorporating H3-thymidine, a color developing method using WST-8 which is a tetrazolium salt, or the like.
  • an antibody that acts on CD40 expressed on the surface of a cell such as a B cell or a tumor cell and affects (suppresses or promotes) or does not affect the proliferation of the CD40-expressing cell is selected.
  • variable region of anti-human CD40 antibody Regarding the antibody that binds to human CD40 in the present invention, cloning of the variable region can be prepared by methods known to those skilled in the art.
  • mRNA encoding the variable region of anti-human CD40 antibody is isolated from a hybridoma producing anti-human CD40 antibody. Isolation of mRNA is performed by a known method such as guanidine ultracentrifugation (Chirgwin, J. M. et al., Biochemistry 1979; 18: 5294-5299), AGPC method (Chomczynski, P.et al., Anal Biochem). 1987; 162: 156-159), etc. to prepare total RNA, and mRNA of interest is prepared using mRNA Purification Kit (Pharmacia). Alternatively, mRNA can be directly prepared by using QuickPrep mRNA Purification Kit (Pharmacia).
  • the desired DNA fragment is purified from the obtained PCR amplification product and ligated with vector DNA. Further, a recombinant vector is prepared from this, introduced into Escherichia coli, etc., and colonies are selected to prepare a desired recombinant vector. Then, the base sequence of the target DNA is confirmed by a known method such as the dideoxynucleotide chain termination method.
  • amino acid residues and CDRs of the light chain variable region and heavy chain variable region can be identified from the publicly available Kabat Database or IMGT (ImMunoGeneTics) Database.
  • humanized anti-CD40 antibody As one of the preferred embodiments of the antibody in the present invention, a chimera in which the constant regions of human ⁇ chain and human IgG1 are linked to the variable regions of the light and heavy chains of a mouse antibody that binds to human CD40. Mention may be made of antibodies. Further preferred embodiments include humanized antibodies that bind to human CD40. Humanized antibodies can be produced using known methods.
  • a humanized antibody is also called a reshaped human antibody, which is a non-human mammal, for example, a mouse antibody complementarity determining region (CDR) grafted to the CDR of a human antibody,
  • CDR complementarity determining region
  • a genetic recombination technique is also known (WO 96/02576).
  • the CDR when the CDR is derived from a mouse antibody, a DNA sequence designed to link the CDR of the mouse antibody and the framework region (FR) of the human antibody is used as a terminal region of both CDR and FR. Synthesize by PCR using several oligonucleotides prepared to have overlapping parts as primers, or artificially synthesize DNA encoding light chain variable region and heavy chain variable region genes Is also possible.
  • the framework region of the human antibody to be linked to the CDR is selected such that the complementarity determining region forms a favorable antigen binding site. If necessary, amino acids in the framework region in the variable region of the antibody may be substituted so that the complementarity determining region of the humanized antibody forms an appropriate antigen binding site (Sato K et al., Cancer Res 1993 ; 53: 851-856).
  • the constant region of a humanized antibody is that of a human antibody.
  • C ⁇ 1, C ⁇ 2, C ⁇ 3, C ⁇ 4 can be used for the heavy chain, and C ⁇ , C ⁇ can be used for the light chain.
  • the constant region of a human antibody may be modified to improve the stability of the antibody or its production.
  • Human antibodies used for humanization may be human antibodies of any isotype such as IgG, IgM, IgA, IgE, IgD, but in the present invention, IgG is preferably used, IgG1 or IgG3 is more preferable, and IgG1 is particularly preferable. Is preferred. IgG1 is effective when an antibody is used as an anticancer agent because of its high cytotoxic activity (Clark MR, Chemical immunology 1997; 65: 88-110).
  • amino acids in the variable region or the constant region may be substituted with other amino acids.
  • the antibody of the present invention may be an antibody with enhanced cytotoxic activity.
  • antibodies with enhanced cytotoxic activity include antibodies lacking fucose, antibodies in which bisecting N-acetylglucosamine (GlcNAc) is added to the sugar chain, and Fc ⁇ receptor by substituting amino acids in the Fc region. Examples thereof include antibodies whose binding activity with the body has been changed. These antibodies with enhanced cytotoxic activity can be prepared by methods known to those skilled in the art.
  • the origin of CDR in a humanized antibody is not particularly limited and may be derived from any animal.
  • sequences of mouse antibody, rat antibody, rabbit antibody, camel antibody and the like can be used, but the CDR sequence of mouse antibody is preferable.
  • the antibody gene is incorporated into an expression vector so that the antibody gene is expressed under the control of an expression control region such as an enhancer or promoter.
  • an expression control region such as an enhancer or promoter.
  • the expression of the antibody gene may be achieved by separately incorporating polynucleotides encoding light or heavy chains into an expression vector and co-transforming host cells, or by using a single polynucleotide encoding light and heavy chains.
  • the host cell may be transformed by incorporating it into the expression vector (WO94 / 11523).
  • humanization of antibodies it is usually difficult to perform humanization while maintaining the functional activity of the antibody from which it was derived (for example, it does not affect cell growth).
  • Anti-CD40 Antibody Conjugated with Cytotoxic Agent Another embodiment of the present invention is a conjugated antibody in which anti-CD40 antibody is bound to various molecules such as cytotoxic drugs and drugs.
  • cytotoxic agents used in the present invention include duocarmycin, duocarmycin analogs and inducers, CC-1065, duocarmycin analogs based on CBI, and duocarmycins based on MCBI. Analogs, duocarmycin analogs based on CCBI, doxorubicin, dolastatin, maytansine, maytansine analogs, DM1, DM2, DM3, DM4, DMI, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP) , Monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), methotrexate, metopterin, dichloromethotrexate, 5-fluorouracil, mitomycin C, mitomycin A, carminomycin, aminopterin, vincristine, taxol, taxotere retinoic acid, butyric acid, N8 It can be exemplified acetyl,
  • the anti-CD40 antibody conjugated with the cytotoxic drug in the present invention can be prepared by a known method by binding the above-mentioned drug and the anti-CD40 antibody.
  • the antibody and the drug may be directly bonded via a linking group or the like possessed by themselves, or may be indirectly bonded via a linker or other substance.
  • linking group when the drug is directly bonded examples include a disulfide bond using an SH group and a bond via maleimide.
  • the intramolecular disulfide bond in the Fc region of the antibody and the disulfide bond of the drug are reduced, and both are bonded by a disulfide bond.
  • Another method is to introduce cysteine into the antibody by genetic engineering.
  • the linker preferably has one or more functional groups that react with the antibody or drug or both.
  • functional groups include amino groups, carboxyl groups, mercapto groups, maleimide groups, pyridinyl groups, and the like.
  • linkers include sulfosuccinimidyl-4- (N-maleimidomethyl) cyclohexane-1-carboxylate (Sulfo-SMCC), N-succinimidyl 4- (maleimidomethyl) cyclohexanecarboxylate (SMCC), ⁇ - Maleimidobutyric acid N-succinimidyl ester (GMBS), ⁇ -maleimidocaproic acid N-hydroxysuccinimide ester (EMCS), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), N- ( ⁇ -maleimidoacetoxy) -succinimide Ester (AMAS), N-succinimidyl 4- (p-maleimidophenyl) -butyrate (SMPB), and N- (p-maleimidophenyl) isocyanate (PMPI), p-aminobenzyloxycarbonyl (PAB), N-male
  • CancerCanResearch 68 (22) 9280 (2008), Nature Biotechnology; 26 (8) 925 (2008), Bio Conjugate Chemistry; 19, 1673 (2008), Cancer Research; 68 (15) ⁇ ⁇ 6300 (2008), or Japanese National Patent Publication No. 2008-516896.
  • Anti-CD40 Antibody Conjugated with Radioisotope Another embodiment of the present invention includes a conjugated antibody in which a radioisotope is labeled with an anti-CD40 antibody. When used as an antitumor agent, cytotoxic radioactive metal elements are preferred.
  • cytotoxic radioactive metal elements examples include yttrium 90 (90Y), rhenium 186 (186Re), rhenium 188 (188Re), copper 67 (67Cu), iron 59 (59Fe), strontium 89 (89Sr), gold 198 (198Au), mercury 203 (203Hg), lead 212 (212Pb), dysprosium 165 (165Dy), ruthenium 103 (103Ru), bismuth 212 (212Bi), bismuth 213 (213Bi), holmium 166 (166Ho), samarium 153 ( 153Sm) and lutetium 177 (177Lu).
  • 90Y, 153Sm, and 177Lu are preferable from the viewpoints of half-life, radiation energy, easy labeling reaction, labeling rate, and complex stability.
  • the antibody is reacted with a metal chelating reagent and then reacted with a radioactive metal element to form a complex.
  • the radioactive metal element is bound to the anti-CD40 antibody via a metal chelating reagent.
  • metal chelating reagents used for such complex formation include (1) 8-hydroxyquinoline, 8-acetoxyquinoline, 8-hydroxyquinaldine, quinolone compounds having a quinoline skeleton, norfloxacin, ofloxacin, spal Quinoline derivatives such as floxacin; (2) compounds such as chloranilic acid, aluminone, thiourea, tetraphenylarsonium chloride; (3) ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), and similar skeletons Dihydroxyethylglycine having, ethylenediaminediacetic acid, ethylenediaminedipropionate hydrochloride, isothiocyanobenzyl EDTA, isothiocyanobenzyl DTPA, methylisothiocyanobenzyl DTPA, cyclohexylisothiocyanobenzyl DTPA, Maleimidopropylamid
  • isothiocyanobenzyl DOTA, methylisothiocyanobenzyl DTPA, and cyclohexylisothiocyanobenzyl DTPA are easy to introduce metal chelates into antibodies, labeling rate, complex stability, etc. preferable.
  • the binding of the radioactive metal element to the anti-CD40 antibody can be performed according to a conventional method.
  • the reaction can be performed by reacting an anti-CD40 antibody with a metal chelate reagent, preparing a labeling precursor in advance, and then reacting with a radioactive metal element.
  • examples of the pharmaceutical composition for a tumor expressing CD40 include a composition containing the anti-human CD40 monoclonal antibody or an antibody-binding fragment thereof.
  • a pharmaceutical composition preferably includes a pharmaceutically acceptable diluent or carrier in addition to the antibody, and may be a mixture with other antibodies or other agents such as antibiotics.
  • Suitable carriers include, but are not limited to, physiological saline, phosphate buffered saline, phosphate buffered saline glucose solution, and buffered saline.
  • the routes of administration are oral routes and parenteral routes including intravenous, intramuscular, subcutaneous and intraperitoneal injection or delivery.
  • the effective amount administered as a combination of an effective amount of the antibody of the present invention and an appropriate diluent and a pharmaceutically usable carrier is 0.1 mg to 100 mg per kg body weight at a time. It is administered at 8 week intervals.
  • Example 1 Amino acid information of human CD40 With reference to SEQ ID NO: 1 (Genbank accession number NP_001241, FIG. 1), a gene encoding soluble CD40 from the full length to amino acid residues 1-173 was artificially synthesized. Full length CD40 was inserted into the pCXN3 vector. In order to produce soluble CD40-Fc, a gene encoding CD40 at amino acid residues 1-173 was inserted immediately before the Fc gene into a pCXN3 vector in which a gene of Fc region derived from mouse IgG2a was incorporated. Vector inserted with gene encoding full-length CD40 introduced into 293T / 17 (ATCC No.
  • the protein was purified by passing through a Protein G sepharose column (GE), and the soluble CD40-Fc protein was replaced with PBS. It was confirmed that the soluble CD40-Fc was purified by Western blotting using SDS-PAGE and anti-human CD40 antibody (BD).
  • GE Protein G sepharose column
  • Example 2 The immunization to mice and the selection of hybridomas will be described.
  • the homology between human CD40 and mouse CD40 is not high as shown in FIG. 2, and it is considered that antibodies against human CD40 can be obtained by immunizing mice.
  • Immunization was started from 6-8 weeks of age using Balb / c mice as immunized animals. The immunization was performed using three immunogens: 1) 293T / 17 or 2) NIH / 3T3, which is a stable expression strain of full-length CD40, and 3) soluble CD40-Fc.
  • the initial immunization was administered with 100 ng / head of pertussis toxin as an adjuvant and 1 ⁇ 10 7 cells / head of full-length CD40 expression strain 293T / 17 or NIH / 3T3 intraperitoneally.
  • the same cells as in the first immunization were immunized with 1 ⁇ 10 6 cells / head under conditions without an adjuvant. Thereafter, a total of 4 doses were given at 1 week intervals.
  • Soluble CD40-Fc was given as the first immunization, and CD40-Fc was intraperitoneally administered with 50 ⁇ g / head, emulsified with pertussis toxin 100 ng / head and Freud's complete adjuvant. Two weeks later, booster immunization was performed with CD40-Fc 25 ⁇ g / head emulsified with Freud's incomplete adjuvant. Thereafter, a total of 4 doses were given at 1 week intervals. Three days before cell fusion, final immunization was performed with full-length CD40-expressing strain BA / F3 at 1.5 ⁇ 10 6 cells / head or soluble CD40-Fc 25 ⁇ g / head in PBS.
  • RPMI1640 medium was added to dilute PEG1500, and PEG1500 was removed by centrifugation. A cell pellet carefully suspended in 10% FBS / RPMI1640 medium was seeded in a 96-well plate at 100 ⁇ L / well and cultured overnight. On the next day, RPMI1640 medium (HAT medium) containing 10% FBS / 1x HAT media supplement / 1x BM-condimed H1 Hybridoma cloning supplement was added at 100 ⁇ L / well. Two to four days after the fusion day, half of the culture medium was replaced with fresh HAT medium, and screening was performed using the culture supernatant after 8 days.
  • Example 3 The preparation of monoclonal antibodies against human CD40 is described.
  • Mouse ascites was performed to obtain each monoclonal antibody.
  • Monocloned hybridomas were cultured and then collected by centrifugation. The collected hybridoma was washed twice with PBS.
  • Ascites was collected when Balb / c mice that had been pre-administered with pristane and adjuvanted 1 to 2 weeks prior to the administration of the hybridoma were ascites collected for 3 to 1.5 months after administration of 1 ⁇ 10 7 hybridomas / head. It was collected.
  • the antibody contained in the ascites was precipitated by 50% ammonium sulfate precipitation.
  • the precipitate was dissolved in PBS, and IgG was purified on a Protein G Sepharose column.
  • the antibody was eluted with 0.1M Glycine-HCl pH 2.7 and neutralized with neutralization buffer. Thereafter, the IgG subclass was identified using the Iso Strip mouse monoclonal antibody isotyping kit (Roche Diagnostics) after replacing with PBS.
  • Table 1 shows immunogens and antibody subclasses for the obtained 25 hybridoma clones (PPAT-071-01 to 25).
  • each hybridoma clone producing the human anti-human CD40 monoclonal antibody of the present invention has a symbol. Named.
  • the term “antibody” after the symbol means an antibody produced by each hybridoma, or a recombinant antibody produced by a host cell carrying an antibody gene isolated from the hybridoma.
  • the name of the hybridoma clone may represent the name of an antibody within a range that is clear from the context.
  • Example 4 Explain the cross-classification between cynomolgus monkey CD40 and mouse CD40 expressing cells.
  • cell lines expressing cynomolgus monkey and mouse CD40 were prepared. From the information on the amino acid residues of the cynomolgus monkey CD40 gene (SEQ ID NO: 2, FIG. 3) and mouse CD40 (SEQ ID NO: 3, FIG. 2), DNAs encoding the respective genes were artificially synthesized. These genes inserted into the pCXN3 vector were introduced into CHO cells (ATCC No. CCL-61) and cultured in the presence of G418 drug to obtain a stable expression strain.
  • Example 5 Explain the epitope classification by CD40 epitope-expressing cells.
  • Ellmark et al. (Immunology 2002; 106: 456-463) have known six partial length CD40 shortened from the N-terminus of CD40 ( D1, D1B2, D2, D2B1, D3, D4 (shown in FIG. 3) were artificially synthesized with DNAs encoding genes with the C-terminal addition of VSV-G tags. These genes were inserted into the pCXN3 vector, and the respective vectors were introduced into 293T cells and expressed transiently.
  • partial length CD40 was confirmed by Western blotting using anti-VSV-G antibody using cell lysate as a sample.
  • Each partial length CD40-expressing 293T cell was reacted with an antibody concentration of 1 ⁇ g / mL and subjected to FACS analysis. As shown in FIG. 4, it did not respond to the partial length CD40-expressing cells not containing the CD40 epitope recognized by the antibody.
  • Table 2 shows a summary of the CD40 epitope of each antibody.
  • PPAT-071-06 NITE BP-01436
  • PPAT-071-07 NITE BP-01437
  • PPAT-071-08 NITE BP-01438
  • PPAT-071-11 NITE BP -01716
  • PPAT-071-14 NITE BP-01439
  • PPAT-071-16 NITE BP-01440
  • PPAT-071-17 NITE BP-01441
  • PPAT-071-18 NITE BP-01442
  • Example 6 A proliferation assay of mouse antibodies against human CD40 expressing cells (Ramos) is described. Using Ramos cells (ATCC No. CRL-1596), which is a B-cell lymphoma expressing CD40, it was examined whether cell proliferation was affected in the presence of antibodies. Ramos cells were prepared at 2.2 ⁇ 10 6 cells / mL in 2% FBS / RPMI1640 medium and seeded on a 24 wells plate at 900 ⁇ L (2 ⁇ 10 5 cells) / well. To this well, 10 ⁇ g / mL of an antibody solution prepared in the same medium was added at 100 ⁇ L / well.
  • Ramos cells ATCC No. CRL-1596
  • An antibody with a well (CD95 expression of 2 times or more) showing a growth rate of 70% or less was regarded as an antibody that suppresses proliferation.
  • Many antibodies having CD40 epitopes at amino acid residues 21-37 or 38-61 of CD40 were found to inhibit proliferation.
  • Example 7 The antitumor effect in the Ramos transplantation model with anti-human CD40 antibody will be described.
  • Six weeks old CB17 / Icr-scidJc1 mice (Claire Japan) were injected subcutaneously with 5 ⁇ 10 6 Ramos cells as tumor cells per mouse.
  • PPAT-071-06 or PPAT-071-18 was intravenously injected on the day the tumor shape reached an average of 230 mm 3 .
  • the dose was 10 mg / kg of anti-CD40 antibody per mouse, and 5 mice each were administered twice a week.
  • the average value of tumor size is shown in FIG.
  • the size of the tumor in all 5 animals was smaller than that at the first antibody administration, and anti-tumor effects were confirmed in PPAT-071-06 and PPAT-071-18 It was.
  • Example 8 The cloning of the variable region of the anti-human CD40 antibody will be described. Using total RNA prepared from each hybridoma cultured as a template, cDNA was synthesized using SuperScript III First Strand Synthesis System (Invitrogen) according to the attached instructions. Amplification of the heavy chain variable region was performed by PCR using ExTag polymerase (Takara Bio) as a template using a forward primer containing the degenerate sequence of the nucleic acid encoding the heavy chain signal sequence and a reverse primer specific to the heavy chain constant region. .
  • ExTag polymerase Takara Bio
  • Amplification of the light chain variable region was performed by PCR using ExTag polymerase as a template using a forward primer containing a degenerate sequence of a nucleic acid encoding a light chain signal sequence and a reverse primer specific to the light chain constant region.
  • the amplified PCR product is purified from a single band of agarose gel electrophoresis using QIAquick Gel Extraction Kit (Qiagen), then cloned into pGEM-T easy vector (Promega), the base sequence is determined, The amino acid residues and CDRs of the chain variable region and light chain variable region were identified.
  • Tables 3 and 4 show the CDR sequences of the light and heavy chains of the antibody having the CD40 epitope at amino acid residues 21-37 or 38-61 of CD40, respectively.
  • Example 9 Production of anti-CD40 humanized antibody is described.
  • Human antibody sequence data published by IMGT was obtained, and consensus sequences were identified for light chain variable regions and heavy chain variable regions.
  • the amino acid sequence of the resulting light chain variable region is shown in SEQ ID NO: 54
  • the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 55.
  • amino acid residues containing the CDRs of the antibodies shown in 1) to 7) below were transplanted to design humanized antibodies.
  • amino acid residues containing each CDR of PPAT-071-17 were transplanted to design humanized antibodies.
  • the amino acid sequences of the light chain variable region and the heavy chain variable region for each designed humanized antibody are shown in Tables 5-1 and 5-2.
  • the DNAs encoding the light chain variable region and heavy chain variable region genes of each humanized antibody designed were artificially synthesized. Expression by inserting the heavy chain variable region gene into the pCXN3 vector with the constant region gene derived from human IgG1, and the light chain variable region gene into the pCXN3 vector with the constant region gene derived from human ⁇ chain The vector was introduced into FreeStyle-293F cells (invitrogen) to produce each humanized antibody. Each humanized antibody produced was present in the culture supernatant and was confirmed to specifically bind to CD40 on Ramos cells.
  • Humanized antibodies of hsPPAT-071-06, hsPPAT-071-07, hsPPAT-071-14, and hsPPAT-071-18 are further produced and purified with a Protein® G column and further purified with an anion column or gel filtration column. And replaced with PBS. As in Examples 4 and 5, each purified humanized antibody was confirmed to have the same characteristics as the original mouse antibody in terms of CD40 epitope and cross-reactivity of heterologous animal CD40.
  • Example 10 A proliferation assay with humanized antibodies is described. Uses Ramos cells that express CD40 and MOLP-8 (DSMZ No.ACC-569), a multiple myeloma that does not express CD40, to affect cell growth in the presence of mouse and humanized antibodies I investigated. Both Ramos cells and MOLP-8 cells were prepared in 2% FBS / RPMI1640 medium at 3.3 ⁇ 10 6 cells / mL, and seeded at 90 ⁇ L (3 ⁇ 10 5 cells) / well in a 96 well plate. To this well, an antibody solution prepared in the same medium was added at a final concentration of 0.01 to 3.0 ⁇ g / mL at 10 ⁇ L / well and cultured at 37 ° C. with 5% CO 2 .
  • FIG. 7 summarizes the results showing the growth rate of wells with respect to each concentration of antibody added, with the wells without addition of antibody alone being 100% growth rate. Concentration dependence was confirmed for both the mouse antibody and the humanized antibody, and the growth rate of the humanized antibody was shown to be suppressed although some antibodies showed a slight increase compared to the mouse antibody.
  • Example 11 The antitumor effect in Ramos transplantation model with anti-CD40 humanized antibody is explained.
  • Six weeks old CB 17 / Icr-scidJc1 mice (CLEA Japan) were injected subcutaneously with 5 ⁇ 10 6 Ramos cells as tumor cells per mouse.
  • the day when tumor shapes reached an average of 270 mm 3 humanized antibodies of hsPPAT-071-06, hsPPAT-071-14, or hsPPAT-071-18 were injected intravenously.
  • the dose was 10 mg / kg of anti-CD40 antibody per mouse, and 5 mice each were administered twice a week.
  • the average value of the size of the tumor shape is shown in FIG. In all 5 animals in the group administered with humanized anti-CD40 antibody 10 mg / kg, the degree of tumor enlargement was delayed compared to the PBS-administered group, confirming the antitumor effect of the humanized antibody.
  • Example 12 The antitumor effect of an antibody conjugated with a cytotoxic drug will be described.
  • the mouse antibody was chemically cross-linked with a cytotoxic agent to examine whether it had an antitumor effect on the cells.
  • the anti-CD40 monoclonal antibody crosslinks DM1SH which is one of the cytotoxic agents maytansinoids, Proliferation assays on Ramos cells in vitro were performed.
  • Sulfo-SMCC (Sulfo-Succinimidyl-4- (N-Maleimidomethyl) Cyclohexane-1-Carboxylate, Pierce) was reacted with 1 mg / mL of antibody at a molar ratio of 30: 1 for 1 hour at room temperature. Then, in order to remove unmodified sulfo-SMCC, it passed through the simple desalting column (Thermo), and the antibody of MCC bridge
  • Ramos cells and Raji cells that characterize the expression of CD40 antigen were selected as target cells, and MOLP-8, which does not show CD40 expression, was selected as a negative control.
  • MOLP-8 which does not show CD40 expression
  • For cells prepare 3.3x10 4 cells / mL (Ramos), 5.5x10 4 cells / mL (Raji), 11x10 4 cells / mL (MOLP-8) in 10% FBS / RPMI1640 medium, and add 90 ⁇ L / well to a 96-well plate. Sowing. DM1-MCC-antibody prepared in the medium was added at 10 ⁇ L / well to a final concentration of 0.0001 to 3 ⁇ g / mL and cultured for 3 days.
  • a proliferation assay was performed using cell counting Kit-8.
  • Table 6 shows the growth rate of each cell in the well when the DM1-MCC-antibody concentration is 0.1 ⁇ g / mL, with the well containing no antibody added as a 100% growth rate. In this culture condition, intact antibodies do not inhibit growth. Moreover, the sensitivity with respect to DM1 of each cell was substantially equivalent (FIG. 9). For PPAT-071-06, PPAT-071-07, and PPAT-071-18, cell proliferation rates are shown in FIGS. 10 to 12 with respect to the added DM1-MCC-antibody concentration.
  • MOLP-8 has a cytotoxic activity. No cytotoxic activity was observed against Ramos and Raji expressing CD40. That is, it was shown that an anti-CD40 antibody conjugated with a cytotoxic drug can specifically kill CD40-expressing cells.
  • the antibody of the present invention can be used as an antitumor agent.

Abstract

La présente invention concerne un anticorps monoclonal présentant une activité stimulante supérieure à celle des anticorps monoclonaux anti-CD40 classiques. Cet anticorps monoclonal anti-CD40 humain, ou un fragment liant l'antigène correspondant, qui présente une activité inhibitrice de la prolifération vis-à-vis des cellules exprimant l'antigène CD-40 humain, en l'absence de cellules effectrices, se lie spécifiquement à : a) un épitope incluant les résidus d'acide aminé 21-37 d'une séquence d'acides aminés du CD40 humain (SEQ ID NO: 1) ; ou b) un épitope incluant les résidus d'acide aminé 38-61 de la séquence d'acides aminés du CD40 humain (SEQ ID NO: 1).
PCT/JP2013/078971 2012-10-26 2013-10-25 Anticorps monoclonal anti-cd-40 humain, et utilisation correspondante WO2014065402A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014543361A JPWO2014065402A1 (ja) 2012-10-26 2013-10-25 抗ヒトｃｄ４０モノクローナル抗体及びその利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012237148 2012-10-26
JP2012-237148 2012-10-26

Publications (1)

Publication Number Publication Date
WO2014065402A1 true WO2014065402A1 (fr) 2014-05-01

Family

ID=50544773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/078971 WO2014065402A1 (fr) 2012-10-26 2013-10-25 Anticorps monoclonal anti-cd-40 humain, et utilisation correspondante

Country Status (2)

Country Link
JP (1) JPWO2014065402A1 (fr)
WO (1) WO2014065402A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017205738A1 (fr) * 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Protéines de liaison bispécifiques se liant à une protéine immunomodulatrice et à un antigène tumoral
WO2017220988A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anticorps multispécifiques pour l'immuno-oncologie
WO2019204756A1 (fr) * 2018-04-20 2019-10-24 Lyvgen Biopharma Co., Ltd. Anticorps anti-cd40 et leurs utilisations
WO2019241730A2 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
WO2021081303A1 (fr) * 2019-10-23 2021-04-29 Lyvgen Biopharma (Suzhou) Co., Ltd. Molécules de liaison anti-cd40 et anticorps bispécifiques les comprenant
WO2021127217A1 (fr) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer
US11186648B2 (en) 2018-09-28 2021-11-30 Lyvgen Biopharma Co., Ltd. Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereof
WO2022006179A1 (fr) 2020-06-29 2022-01-06 Flagship Pioneering Innovations V, Inc. Virus modifiés pour favoriser la thanotransmission et leur utilisation dans le traitement du cancer
JP2022522709A (ja) * 2019-03-04 2022-04-20 ベイジン マブワークス バイオテック カンパニー リミテッド Ｃｄ４０に結合する抗体およびその使用
US11497769B2 (en) * 2017-09-21 2022-11-15 WuXi Biologics Ireland Limited Anti-CD19 antibodies
US11926672B2 (en) 2019-12-20 2024-03-12 Amgen Inc. Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A.-C. MALMBORG HAGER ET AL.: "Affinity and Epitope Profiling of Mouse Anti-CD40Monoclonal Antibodies.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 57, no. 6, 2003, pages 517 - 524 *
ALISON L. TUTT ET AL.: "Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.", J. IMMUNOL., vol. 161, no. 6, 1998, pages 3176 - 3185 *
JOEL G. TURNER ET AL.: "Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.", J. IMMUNOL., vol. 166, no. 1, 2001, pages 89 - 94 *
JOSEPH A. FRANCISCO ET AL.: "Agonistic Properties and in Vivo Antitumor Activity of the Anti-CD40 Antibody SGN-14.", CANCER RESEARCH, vol. 60, no. 12, 2000, pages 3225 - 3231 *
S. FUNAKOSHI ET AL.: "Inhibition of human B-cell lymphoma growth by CD40 stimulation.", BLOOD, vol. 83, no. 10, 1994, pages 2787 - 2794 *
TIMOTHY S. LEWIS ET AL.: "Distinct Apoptotic Signaling Characteristics of the Anti-CD40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non- Hodgkin Lymphoma.", CLINICAL CANCER RESEARCH, vol. 17, no. 14, 2011, pages 4672 - 4681 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10233258B2 (en) 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. Bispecific binding proteins that bind CD40 and mesothelin
WO2017205738A1 (fr) * 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Protéines de liaison bispécifiques se liant à une protéine immunomodulatrice et à un antigène tumoral
WO2017220988A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anticorps multispécifiques pour l'immuno-oncologie
WO2017220989A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 et cytokines il-2
WO2017220990A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anticorps anti-pd-l1
US11497769B2 (en) * 2017-09-21 2022-11-15 WuXi Biologics Ireland Limited Anti-CD19 antibodies
WO2019204756A1 (fr) * 2018-04-20 2019-10-24 Lyvgen Biopharma Co., Ltd. Anticorps anti-cd40 et leurs utilisations
WO2019241730A2 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
US11186648B2 (en) 2018-09-28 2021-11-30 Lyvgen Biopharma Co., Ltd. Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereof
JP2022522709A (ja) * 2019-03-04 2022-04-20 ベイジン マブワークス バイオテック カンパニー リミテッド Ｃｄ４０に結合する抗体およびその使用
JP7206566B2 (ja) 2019-03-04 2023-01-18 ベイジン マブワークス バイオテック カンパニー リミテッド Ｃｄ４０に結合する抗体およびその使用
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
WO2021081303A1 (fr) * 2019-10-23 2021-04-29 Lyvgen Biopharma (Suzhou) Co., Ltd. Molécules de liaison anti-cd40 et anticorps bispécifiques les comprenant
WO2021127217A1 (fr) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer
US11926672B2 (en) 2019-12-20 2024-03-12 Amgen Inc. Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
WO2022006179A1 (fr) 2020-06-29 2022-01-06 Flagship Pioneering Innovations V, Inc. Virus modifiés pour favoriser la thanotransmission et leur utilisation dans le traitement du cancer

Also Published As

Publication number Publication date
JPWO2014065402A1 (ja) 2016-09-08

Similar Documents

Publication Publication Date Title
WO2014065402A1 (fr) Anticorps monoclonal anti-cd-40 humain, et utilisation correspondante
US11136413B2 (en) PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
US20230218776A1 (en) Anti-ntb-a antibodies and related compositions and methods
WO2014065403A1 (fr) Anticorps monoclonal anti-cd40 humain et son utilisation
JP6273214B2 (ja) がんを処置するためのインテグリンαｖβ６に対する抗体およびその使用
JP6447130B2 (ja) 癌の治療及び／又は予防用医薬組成物
US20190375841A1 (en) Anti-ntb-a antibodies and related compositions and methods
US11497769B2 (en) Anti-CD19 antibodies
JP6077745B2 (ja) 抗ポドプラニン抗体、及び抗ポドプラニン抗体を含む医薬組成物
KR20160127825A (ko) 항-mcam 항체 및 관련된 사용 방법
CN113645996A (zh) 抗claudin 18抗体及其使用方法
KR20210132664A (ko) 항pd-l1 항체 및 그의 용도
US20230080842A1 (en) Tetravalent symmetric bispecific antibodies
JP2022500004A (ja) 抗ｃｄ４０抗体及びその使用
WO2023143343A1 (fr) Anticorps anti-her2/trop2 et leurs utilisations
WO2022179466A1 (fr) Anticorps anti-siglec15 et utilisation associée
WO2017061602A1 (fr) Anticorps apte à se lier spécifiquement à la molécule cd147, et son utilisation
JP6847434B2 (ja) 抗ポドプラニン抗体
CN117881701A (zh) 抗cll-1抗体及其用途
CN117430697A (zh) 抗mct1抗体及其用途
EA044092B1 (ru) Анти-ntb-a антитела и терапевтические композиции, их содержащие

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13848262

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014543361

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13848262

Country of ref document: EP

Kind code of ref document: A1